NRG Therapeutics
PrivateLast Round
Series B
Sep 8, 2025
Total Funding Raised
$95.4M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
NRG Therapeutics is a biotechnology company developing disease-modifying, brain-penetrant small molecule inhibitors of the mitochondrial permeability transition pore (mPTP) to treat neurodegenerative disorders such as Parkinson's disease and ALS.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
NRG Therapeutics Comparables
Compare NRG Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| MitoRx Therapeutics | 87% | |
| Lucy Therapeutics | 85% | |
| Morningside | 81% |
NRG Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Sep 8, 2025 | ||||
| Grant | Oct 31, 2024 | ||||
| Grant | Sep 5, 2024 | ||||
| Grant | Feb 22, 2023 | ||||
| Series A | Nov 9, 2022 | ||||
Grant | May 30, 2022 |
NRG Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Innovate UK | Grant |
| Omega Funds | Series B, Series A |
| SV Health Investors | Series B |
| Parkinson's UK | Series A, Seed, Series B |
| M Ventures | Series B |
| British Business Bank | Series B |
| The Michael J. Fox Foundation for Parkinson's Research | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 27, 2026
Monthly visitors grew 107% MoM, reaching 1.9K.
- Oct 23, 2025
Kathryn Oliver appointed to newly created role.
Recent news
Latest coverage and updates
- hiresSep 3, 2026
NRG Therapeutics Ltd hired Claus as Chief Medical Officer on Aug 1st '26.
- attends_eventAug 25, 2026
NRG Therapeutics Ltd attended event ALS Nexus conference on Aug 26th '23.
- hiresAug 3, 2026
NRG Therapeutics Ltd was planning to hire Sundgreen as Chief Medical Officer on Aug 1st '26.
- hiresAug 3, 2026
NRG Therapeutics Ltd hired Claus Sundgreen as Chief Medical Officer on Aug 1st '26.
- hiresAug 3, 2026
NRG Therapeutics Ltd was planning to hire Claus as Chief Medical Officer on Aug 1st '26.
NRG Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about NRG Therapeutics's valuation, stock price, and market status.
Is NRG Therapeutics a public or private company?
NRG Therapeutics is a private company.
What is the current stock price of NRG Therapeutics?
NRG Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is NRG Therapeutics worth (valuation)?
Valuation information for NRG Therapeutics is not publicly available.
Can I buy NRG Therapeutics stock?
NRG Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was NRG Therapeutics's last funding round?
NRG Therapeutics's most recent funding round was Series B on September 8, 2025.
Who are the main investors in NRG Therapeutics?
Key investors in NRG Therapeutics include Omega Funds, SV Health Investors.
Will NRG Therapeutics IPO soon?
No public IPO plans have been announced for NRG Therapeutics.
How can I track NRG Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor NRG Therapeutics's secondary market activity and sign up for updates.